re: #468 Backwoods_Sleuth

More on that:

Gilead Sciences said Wednesday preliminary results of a coronavirus drug trial showed at least 50% of patients treated with a 5-day dosage of antiviral drug remdesivir improved and more than half were discharged from the hospital within two weeks.

The company also said another trial by the National Institute of Allergy and Infectious Diseases met its main goal. It did not provide further details, however.

Shares of Gilead were up more than 3% in midmorning trading.

The clinical trial involved 397 patients with severe cases of Covid-19. The severe study is “single-arm,” meaning it did not evaluate the drug against a control group of patients who didn’t receive the drug.